Chief Executive Officer and President
BiPar Sciences

Hoyoung Huh, M.D., Ph.D. is currently President and Chief Executive Officer of BiPar Sciences, an oncology drug development company focused in novel DNA repair inhibitors for breast, ovarian and brain cancers, located in Northern California.  BiPar Sciences recently announced a merger with sanofi-aventis for $500 million and will remain as a wholly-owned subsidiary.

Prior to joining BiPar, Dr. Huh served as Chief Operating Officer and Head of the PEGylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases.  At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies, including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG, and Roche Holding Ltd. 

Prior to Nektar, Dr. Huh was a Partner at McKinsey and Company, where he focused primarily in the biopharmaceutical sector in the United States, Europe and Asia with areas of expertise in licensing, mergers and acquisitions and innovative product launches.

As an industry thought leader, Dr. Huh speaks frequently about licensing, mergers and acquisitions, innovative product development and commercialization strategies. He currently serves on the Board of Directors at BayBio (a biotechnology industry association), Nektar Therapeutics (public biotech), SciDose (private biotech), and Interplast (medical non-profit).

Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor’s degree in biochemistry from Dartmouth College.